Real-World Experience With Acute Infusion Reactions to Ustekinumab at 2 Large Tertiary Care Centers.
Elizabeth A SpencerJami KinnucanJulie WangMarla C DubinskyPublished in: Crohn's & colitis 360 (2020)
In this large, real-world study of acute infusion reactions to ustekinumab, the rate was similar to that seen in clinical trials-0.8%-3%.